A phase I trial of ramucirumab,
a human monoclonal antibody against the vascular endothelial growth factor - 2 (VEGFR - 2) receptor, in children with refractory solid tumors, including CNS tumors (NCT02564198).
A phase I trial of ramucirumab,
a human monoclonal antibody against the vascular endothelial growth factor - 2 (VEGFR - 2) receptor, in children with refractory solid tumors, including CNS tumors -LRB-
Key Highlight: • Facilitated the introduction of HUMIRA (adalimumab) for the healthcare professionals as the latest and the only fully
human monoclonal antibody against TNF for the treatment of moderate to severe psoriasis in patient failed at least on two DMARD's.
Not exact matches
Cells were first probed with a primary mouse
monoclonal antibody against human HMOX1 (Abcam) diluted in PBS containing 1 % BSA, 0.01 % Triton X-100 for 1 hour, washed twice, and then probed with a secondary goat anti-mouse Alexa 488
antibody (Invitrogen) for 1 hour.